@MelissaGLechner Profile picture

Melissa G. Lechner, MD, PhD

@MelissaGLechner

Physician Scientist studying cancer immunotherapy-IrAEs and thyroid cancer. Onco-Endocrinology Program @UCLA.

Similar User
Iram Hussain photo

@DrIramHussain

Kaniksha Desai photo

@kanikshadesai

Iñigo Landa photo

@inigo_landa

Bryan Haugen photo

@bryan_haugen

Afreen Shariff, MD photo

@afreenshariffmd

Maria Papaleontiou, MD photo

@MariaPapaleont1

aime franco photo

@amos18

Amanda Perl photo

@amandaperl

Rebecca Schweppe PhD photo

@SchweppeRebecca

Increased IRAEs in Breast Cancer Patients Treated with RANKL inhibitor Denosumab + Checkpoint Inhibitor - Podium talk at San Antonio Breast Cancer Symposium by Dr. LeVee @UCLA @AlexisLeVee @ Cityofhope @SABCSSanAntonio wix.to/e7qmcW5


Congratulations to Sarah and Nicole - Uncovering the pathogenesis and potential therapy for ICI-Diabetes at Endo Society this week.#Endo2024 wix.to/8rciuVB


Can't wait to read this - always insightful work from the Landa Lab

Our manuscript "Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes" is now available at @CCR_AACR A thread [1/15] aacrjournals.org/clincancerres/…



Shedding new light on the dark side of cancer immunotherapy - mechanisms of IRAEs. Just out in @ScienceTM, grateful for support from @UCLAHealth and @AmThyroidAssn and my collaborators @DoctorAngell @MaureenSuLab wix.to/yPSqMbG


Melissa G. Lechner, MD, PhD Reposted

1/25. Our work out in @JCO_ASCO! Real-world report from the CATCH-IT consortium. Fortunate to share this journey w/ co-authors, co-first authors @adib_Elio, @TalalZarif1 and under the mentorship of #naqashlab @sonpavde! @YaleCancer, @DanaFarberNews@YaleIMed Tweetorial below:


Tackling checkpoint inhibitor endocrine autoimmune toxicities with great colleagues at the @fredhutch - youtube.com/watch?v=8U3eBl…

Tweet Image 1

Check it out from Dr. Willy Hugo @UCLA New insights into anti-PD1 response in melanoma: Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors biorxiv.org/content/10.110…


Great to see my dear medical school friend @AlexisEDixonMD being awesome! Wouldn’t trust anyone else with my precious runner feet. laweekly.com/the-heal-insti…


Enjoyed speaking about immunology with Jatin and Eugenio of @AntibuddiesP this week - check out their other episodes immunology and human disease, too! twitter.com/AntibuddiesP/s…

We sat down with Dr. Melissa Lechner (@MelissaGLechner) from the UCLA David Geffen School of Medicine to discuss her recent paper about the mechanisms behind immune checkpoint inhibitor-induced autoimmune thyroiditis. Check out the discussion here. open.spotify.com/episode/5rWGv0…



Melissa G. Lechner, MD, PhD Reposted

We sat down with Dr. Melissa Lechner (@MelissaGLechner) from the UCLA David Geffen School of Medicine to discuss her recent paper about the mechanisms behind immune checkpoint inhibitor-induced autoimmune thyroiditis. Check out the discussion here. open.spotify.com/episode/5rWGv0…


Melissa G. Lechner, MD, PhD Reposted

#JI_TopRead from @Maureen_Su_Lab @dgsomucla @UCLA | Inhibition of #IL17A Protects against #Thyroid Immune-related Adverse Events while Preserving Checkpoint Inhibitor #Antitumor Efficacy | ow.ly/pXJv50KkrxJ #ReadTheJI #immunology

Tweet Image 1

melissalechner.wixsite.com/melissalechner… Congratulations to Aline Hoang, our fabulous staff research associate who will be heading to Drexel for medical school this Fall.


Thyroid Health Blog: TERT promoter mutations in thyroid cancers thyroid.org/thyroid-promot… Check out this great summary of TERT mutations in thyroid cancer by @inigo_landa at BWH/DFCI


Loading...

Something went wrong.


Something went wrong.